[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607362":3},{"organization":4,"outcomesModule":7,"designInfo":39,"detailedDescription":38,"studyPopulation":38,"armGroups":48,"interventions":59,"overallOfficials":65,"centralContacts":73,"locations":78,"responsibleParty":179,"collaborators":181,"id":184,"slug":38,"hasResults":185,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":185,"sex":191,"minAge":192,"maxAge":38,"enrollmentInfo":193,"targetDuration":38,"studyType":196,"phases":197,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":100,"whyStopped":38,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},{"fullName":5,"class":6},"Region Stockholm","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":38},[9],{"measure":10,"description":11,"timeFrame":12},"Atrial fibrillation recurrence","Time to first AF recurrence detected with an ECG- monitoring device within 30 days after planned elective electrical cardioversion.","30 days after elective electrical cardioversion",[14,17,19,23,26,30,34],{"measure":15,"description":16,"timeFrame":12},"Proportion of patients in SR at 30 days","Proportion of patients in SR 30 days after cardioversion.",{"measure":18,"description":18,"timeFrame":12},"Proportion of patients without any atrial fibrillation recurrence at 30 days",{"measure":20,"description":21,"timeFrame":22},"Time to spontaneous return to sinus rhythm before electrical cardioversion","Time to spontaneous return to sinus rhythm measured from randomization to electrical cardioversion (max 26 days)","Up to 26 days",{"measure":24,"description":25,"timeFrame":22},"Spontaneous return to sinus rhythm before cardioversion.","Number of patients with return to sinus rhythm at time of electrical cardioversion (maximum 26 days from randomization)",{"measure":27,"description":28,"timeFrame":29},"Success of cardioversion","Discharged with sinus rhythm after electric cardioversion","Periprocedural",{"measure":31,"description":32,"timeFrame":33},"Total number of days with atrial fibrillation","Total number of days with AF recordings during the 30 days following cardioversion.","From day of electric cardioversion to 30 days after",{"measure":35,"description":36,"timeFrame":37},"Absence of clinical atrial fibrillation recording","Absence of clinical atrial fibrillation recurrence (12-lead ECG-verified) during follow-up after cardioversion or after spontaneous return to SR (before cardioversion).","From randomization to 30 days after electric cardioversion",null,{"allocation":40,"interventionModel":41,"interventionModelDescription":42,"primaryPurpose":43,"observationalModel":38,"timePerspective":38,"maskingInfo":44},"RANDOMIZED","PARALLEL","Prospective randomized open blinded end-point (PROBE) study","TREATMENT",{"masking":45,"maskingDescription":38,"whoMasked":46},"SINGLE",[47],"OUTCOMES_ASSESSOR",[49,53],{"label":50,"type":51,"description":52,"interventionNames":38},"Usual care","NO_INTERVENTION","Standard of care",{"label":54,"type":55,"description":56,"interventionNames":57},"Dapagliflozin","EXPERIMENTAL","Tablet Dapagliflozin 10 mg once daily",[58],"Drug: Dapagliflozin 10 mg once daily",[60],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":38},"DRUG","Dapagliflozin 10 mg once daily","Tablet Dapagliflozin 10 mg orally during from randomization for maximum 56 days.",[54],[66,70],{"name":67,"affiliation":68,"role":69},"Karolina Szummer, MD PhD","Karolinska Institutet","PRINCIPAL_INVESTIGATOR",{"name":71,"affiliation":72,"role":69},"Ziad Hijazi, MD PhD","Dept. of Medical Sciences, Uppsala University, Uppsala, Sweden",[74],{"name":67,"role":75,"phone":76,"phoneExt":38,"email":77},"CONTACT","+4681238000","karolina.szummer@regionstockholm.se",[79,98,114,129,139,150,165],{"facility":80,"status":81,"city":82,"state":38,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":92},"Linköping university hosptial","NOT_YET_RECRUITING","Linköping","58225","Sweden","SE",{"type":87,"coordinates":88},"Point",[89,90],15.62157,58.41086,{"lat":90,"lon":89},[93,97],{"name":94,"role":75,"phone":95,"phoneExt":38,"email":96},"Lars O Karlsson, MD PhD","+4610-103 00 00","Lars.O.Karlsson@regionostergotland.se",{"name":94,"role":69,"phone":38,"phoneExt":38,"email":38},{"facility":99,"status":100,"city":101,"state":38,"zip":102,"country":84,"countryCode":85,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Örebro University hospital","RECRUITING","Örebro","70382",{"type":87,"coordinates":104},[105,106],15.2066,59.27412,{"lat":106,"lon":105},[109,113],{"name":110,"role":75,"phone":111,"phoneExt":38,"email":112},"Anna Björkenheim, MD PhD","+46 19-602 10 00","anna.bjorkenheim@regionorebrolan.se",{"name":110,"role":69,"phone":38,"phoneExt":38,"email":38},{"facility":115,"status":81,"city":116,"state":38,"zip":117,"country":84,"countryCode":85,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Södersjukhuset","Stockholm","11861",{"type":87,"coordinates":119},[120,121],18.06871,59.32938,{"lat":121,"lon":120},[124,128],{"name":125,"role":75,"phone":126,"phoneExt":38,"email":127},"Joakim Olbers, MD PhD","+46 8-123 610 00","joakim.olbers@regionstockholm.se",{"name":125,"role":69,"phone":38,"phoneExt":38,"email":38},{"facility":130,"status":100,"city":116,"state":38,"zip":131,"country":84,"countryCode":85,"cosmosGeoPoint":132,"geoPoint":134,"contacts":135},"Karolinska University Hospital","14186",{"type":87,"coordinates":133},[120,121],{"lat":121,"lon":120},[136,138],{"name":67,"role":75,"phone":137,"phoneExt":38,"email":77},"+46812386719",{"name":67,"role":69,"phone":38,"phoneExt":38,"email":38},{"facility":140,"status":81,"city":116,"state":38,"zip":141,"country":84,"countryCode":85,"cosmosGeoPoint":142,"geoPoint":144,"contacts":145},"Danderyds Hospital","18527",{"type":87,"coordinates":143},[120,121],{"lat":121,"lon":120},[146],{"name":147,"role":75,"phone":148,"phoneExt":38,"email":149},"Johan Engdahl, Professor, MD PhD","+468-123 550 00","johan.engdahl@regionstockholm.se",{"facility":151,"status":81,"city":152,"state":38,"zip":153,"country":84,"countryCode":85,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Norrlands universitetssjukhus","Umeå","90185",{"type":87,"coordinates":155},[156,157],20.25972,63.82842,{"lat":157,"lon":156},[160,164],{"name":161,"role":75,"phone":162,"phoneExt":38,"email":163},"Ioannis Kotsoularis, MD PhD","+4690-785 00 00","ioannis.katsoularis@umu.se",{"name":161,"role":69,"phone":38,"phoneExt":38,"email":38},{"facility":166,"status":81,"city":167,"state":38,"zip":168,"country":84,"countryCode":85,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Akademiska sjukhuset","Uppsala","75389",{"type":87,"coordinates":170},[171,172],17.63889,59.85882,{"lat":172,"lon":171},[175,178],{"name":71,"role":75,"phone":176,"phoneExt":38,"email":177},"+4618-611 00 00","ziad.hijazi@uu.se",{"name":71,"role":69,"phone":38,"phoneExt":38,"email":38},{"type":180,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR",[182],{"name":68,"class":183},"OTHER","100607362",false,"NCT07187570","RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care","RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Open-label Treatment With Dapagliflozin or Usual Care","RECUR-AF","Inclusion Criteria:\n\n* Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date.\n* Age ≥ 55 years.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Current treatment with an SGLT2 inhibitor.\n* Prior\u002Fcurrent diagnosis of heart failure.\n* Type 1 diabetes mellitus.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 25 mL\u002Fmin\u002F1.73m2.\n* Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days).\n* Contraindications to SGLT2 inhibitors.\n* Any condition or circumstance in which the patient should not participate in the study according to the study investigator.","ALL","55 Years",{"count":194,"type":195},1600,"ESTIMATED","INTERVENTIONAL",[198],"PHASE3","The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is:\n\n• Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation?\n\nResearchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation.\n\nPersons with atrial fibrillation who are planned for an electric cardioversion will:\n\n* Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days\n* Undergo a planned electric cardioversion of the atrial fibrillation\n* Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days",[201],"Atrial Fibrillation (AF)",[203,204,205,206],"dapagliflozin","sodium-glucose transport-2 inhibitor","electric cardioversion","hand-held ECG device","2025-09-18",{"date":209,"type":210},"2025-09-23","ACTUAL",{"date":212,"type":210},"2025-06-03",{"date":214,"type":195},"2027-12",{"name":5,"class":6},7]